Norwegian Institute of Public Health, Oslo, Norway.
PLoS One. 2020 Apr 2;15(4):e0231040. doi: 10.1371/journal.pone.0231040. eCollection 2020.
MicroRNAs (miRNAs) have been linked to several diseases and to regulation of almost every biological process. This together with their stability while freely circulating in blood suggests that they could serve as minimal-invasive biomarkers for a wide range of diseases. Successful miRNA-based biomarker discovery in plasma is dependent on controlling sources of preanalytical variation, such as cellular contamination and hemolysis, as they can be major causes of altered miRNA expression levels. Analysis of plasma quality is therefore a crucial step for the best output when searching for novel miRNA biomarkers.
Plasma quality was assessed by three different methods in samples from mother-child duos (maternal and cord blood, N = 2x38), with collection and storage methods comparable to large cohort study biobanks. Total RNA was isolated and the expression profiles of 201 miRNAs was obtained by qPCR to identify differentially expressed miRNAs in cord and maternal plasma samples.
All three methods for quality assurance indicate that the plasma samples used in this study are of high quality with very low levels of contamination, suitable for analysis of circulating miRNAs. We identified 19 significantly differentially expressed miRNAs between cord and maternal plasma samples (paired t-tests, FDR<0.05, and fold change>±1.5), and we observed low correlation of miRNA transcript levels between cord and maternal samples throughout our dataset.
Our findings suggest that good quality plasma samples suitable for miRNA profiling can be achieved from samples collected and stored by large biobanks. Incorporation of extensive quality control measures, such as those established here, would be beneficial for future projects. The overall low correlation of miRNA expression between cord and maternal samples is an interesting observation, and promising for our future studies on identification of miRNA-based biomarkers in cord blood plasma, considering that these samples were collected at term and some exchange of blood components between cord and maternal blood frequently occur.
MicroRNAs(miRNAs)与多种疾病有关,几乎调控着所有的生物过程。miRNAs 能够自由地在血液中循环,并且稳定性较好,这表明它们可以作为多种疾病微创性生物标志物。miRNA 作为生物标志物在血浆中成功应用,取决于控制分析前变化的来源,如细胞污染和溶血,因为它们可能是改变 miRNA 表达水平的主要原因。因此,分析血浆质量是寻找新型 miRNA 生物标志物时获得最佳结果的关键步骤。
在母子二人组(母亲和脐带血,N=2x38)的样本中,通过三种不同的方法评估血浆质量,收集和储存方法与大型队列研究生物库相似。提取总 RNA,通过 qPCR 获得 201 个 miRNA 的表达谱,以鉴定脐带血和母血血浆样本中差异表达的 miRNA。
三种质量保证方法均表明,本研究中使用的血浆样本质量高,污染水平极低,适合分析循环 miRNA。我们鉴定了 19 个在脐带血和母血血浆样本中差异表达的 miRNA(配对 t 检验,FDR<0.05,倍数变化>±1.5),并且在整个数据集观察到 miRNA 转录水平在脐带血和母血样本之间相关性低。
我们的研究结果表明,通过大型生物库收集和储存的样本可以获得适合 miRNA 分析的高质量血浆样本。纳入广泛的质量控制措施,如我们在此建立的措施,将有助于未来的项目。脐带血和母血样本之间 miRNA 表达总体相关性低是一个有趣的观察结果,考虑到这些样本是在足月时采集的,并且脐带血和母血之间经常发生血液成分交换,这对我们未来在脐带血血浆中鉴定 miRNA 为基础的生物标志物的研究很有希望。